Is Kymera Therapeutics Stock a Good Investment?
Kymera Therapeutics Investment Advice | KYMR |
- Examine Kymera Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Kymera Therapeutics' leadership team and their track record. Good management can help Kymera Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Kymera Therapeutics' business and its evolving consumer preferences.
- Compare Kymera Therapeutics' performance and market position to its competitors. Analyze how Kymera Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Kymera Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Kymera Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Kymera Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Kymera Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Kymera Therapeutics Stock
Researching Kymera Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of Kymera Therapeutics was now reported as 12.88. The company has Price/Earnings To Growth (PEG) ratio of 0.64. Kymera Therapeutics recorded a loss per share of 2.98. The entity had not issued any dividends in recent years.
To determine if Kymera Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Kymera Therapeutics' research are outlined below:
| Kymera Therapeutics generated a negative expected return over the last 90 days | |
| Kymera Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 47.07 M. Net Loss for the year was (223.86 M) with loss before overhead, payroll, taxes, and interest of (193.18 M). | |
| Kymera Therapeutics currently holds about 392.31 M in cash with (194.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.61. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Discretionary transaction by Baker Bros. Advisors Lp of tradable shares of Kymera Therapeutics subject to Rule 16b-3 |
Kymera Therapeutics Quarterly Accounts Payable |
|
Kymera Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Kymera Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kymera Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Kymera Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Kymera Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-08-09 | 2022-06-30 | -0.7 | -0.78 | -0.08 | 11 | ||
2022-02-24 | 2021-12-31 | -0.57 | -0.66 | -0.09 | 15 | ||
2024-08-07 | 2024-06-30 | -0.68 | -0.58 | 0.1 | 14 | ||
2025-02-20 | 2024-12-31 | -0.7882 | -0.89 | -0.1018 | 12 | ||
2024-05-02 | 2024-03-31 | -0.73 | -0.62 | 0.11 | 15 | ||
2021-11-10 | 2021-09-30 | -0.42 | -0.56 | -0.14 | 33 | ||
2021-05-06 | 2021-03-31 | -0.15 | -0.29 | -0.14 | 93 | ||
2024-02-22 | 2023-12-31 | -0.4 | -0.25 | 0.15 | 37 |
Kymera Therapeutics Target Price Consensus
Kymera target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Kymera Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 20 | Strong Buy |
Most Kymera analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Kymera stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Kymera Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationKymera Therapeutics Target Price Projection
Kymera Therapeutics' current and average target prices are 33.70 and 59.11, respectively. The current price of Kymera Therapeutics is the price at which Kymera Therapeutics is currently trading. On the other hand, Kymera Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Kymera Therapeutics Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Kymera Therapeutics Target Price
Kymera Therapeutics Analyst Ratings
Kymera Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Kymera Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Kymera Therapeutics' financials, market performance, and future outlook by experienced professionals. Kymera Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Kymera Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kymera Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kymera Therapeutics backward and forwards among themselves. Kymera Therapeutics' institutional investor refers to the entity that pools money to purchase Kymera Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 1.1 M | Redmile Group, Llc | 2024-12-31 | 1.1 M | Rock Springs Capital Management Lp | 2024-12-31 | 1 M | Merck & Co Inc | 2024-12-31 | 772.2 K | Jennison Associates Llc | 2024-12-31 | 716.9 K | Deerfield Management Co | 2024-12-31 | 593 K | Woodline Partners Lp | 2024-12-31 | 537.4 K | Avidity Partners Management Lp | 2024-12-31 | 500 K | Ubs Group Ag | 2024-12-31 | 469.8 K | T. Rowe Price Associates, Inc. | 2024-12-31 | 6.9 M | Baker Bros Advisors Lp | 2024-12-31 | 6 M |
Kymera Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.11 B.Market Cap |
|
Kymera Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.27) | (0.25) |
Determining Kymera Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Kymera Therapeutics is a good buy. For example, gross profit margin measures Kymera Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Kymera Therapeutics' profitability and make more informed investment decisions.
Evaluate Kymera Therapeutics' management efficiency
Kymera Therapeutics has return on total asset (ROA) of (0.2065) % which means that it has lost $0.2065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3638) %, meaning that it created substantial loss on money invested by shareholders. Kymera Therapeutics' management efficiency ratios could be used to measure how well Kymera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.3. At this time, Kymera Therapeutics' Net Tangible Assets are relatively stable compared to the past year. As of 03/24/2025, Non Current Assets Total is likely to grow to about 491.2 M, while Total Current Assets are likely to drop slightly above 389.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.14 | 5.77 | |
| Tangible Book Value Per Share | 11.14 | 5.77 | |
| Enterprise Value Over EBITDA | (13.81) | (14.50) | |
| Price Book Value Ratio | 3.61 | 3.79 | |
| Enterprise Value Multiple | (13.81) | (14.50) | |
| Price Fair Value | 3.61 | 3.79 | |
| Enterprise Value | 3 B | 1.6 B |
Kymera Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 2.227 |
Basic technical analysis of Kymera Stock
As of the 24th of March, Kymera Therapeutics secures the Risk Adjusted Performance of (0.07), mean deviation of 2.84, and Standard Deviation of 3.82. Kymera Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kymera Therapeutics variance and skewness to decide if Kymera Therapeutics is priced some-what accurately, providing market reflects its recent price of 33.7 per share. Given that Kymera Therapeutics has information ratio of (0.07), we recommend you to check Kymera Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.Kymera Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kymera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kymera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kymera Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kymera Therapeutics' Outstanding Corporate Bonds
Kymera Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kymera Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kymera bonds can be classified according to their maturity, which is the date when Kymera Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Kymera Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Kymera Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 2.84 | |||
| Coefficient Of Variation | (1,205) | |||
| Standard Deviation | 3.82 | |||
| Variance | 14.59 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 23.03 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 5.5 | |||
| Skewness | (0.62) | |||
| Kurtosis | 2.25 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 2.84 | |||
| Coefficient Of Variation | (1,205) | |||
| Standard Deviation | 3.82 | |||
| Variance | 14.59 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.23) | |||
| Total Risk Alpha | (0.04) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 23.03 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 5.5 | |||
| Skewness | (0.62) | |||
| Kurtosis | 2.25 |
Consider Kymera Therapeutics' intraday indicators
Kymera Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kymera Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 32352.66 | |||
| Daily Balance Of Power | 0.4234 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 33.91 | |||
| Day Typical Price | 33.84 | |||
| Price Action Indicator | 0.37 | |||
| Period Momentum Indicator | 1.16 |
Kymera Therapeutics Corporate Filings
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify | |
F4 | 13th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Kymera Stock media impact
Far too much social signal, news, headlines, and media speculation about Kymera Therapeutics that are available to investors today. That information is available publicly through Kymera media outlets and privately through word of mouth or via Kymera internal channels. However, regardless of the origin, that massive amount of Kymera data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kymera Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kymera Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kymera Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kymera Therapeutics alpha.
Kymera Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kymera Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kymera Therapeutics Historical Investor Sentiment
Investor biases related to Kymera Therapeutics' public news can be used to forecast risks associated with an investment in Kymera. The trend in average sentiment can be used to explain how an investor holding Kymera can time the market purely based on public headlines and social activities around Kymera Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Kymera Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Kymera Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Kymera Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Kymera Therapeutics.
Kymera Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts
Kymera Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Kymera Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Kymera Therapeutics' options.
Kymera Therapeutics Corporate Management
| Jared MD | Chief Officer | Profile | |
| DPhil DPHIL | CoFounder Chairman | Profile | |
| Justine Koenigsberg | Vice Relations | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Karen Weisbach | Head Culture | Profile | |
| Juliet BA | Head Research | Profile | |
| Melissa Brody | VP Devel | Profile |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.